⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Figure S3 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S3: Lurbinectedin treatment induces regulators of the DNA damage response pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chakraborty et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875239f9 https://doi.org/10.1158/1078-0432.27032626.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.2024
2Data from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.2024
3Abstract 6554: Lurbinectedin induces multimodal immune activation and augments the anti-tumor immune response in small-cell lung cancer2024 · 2 citations
4207P Lurbinectedin induces multimodal immune activation and augments the anti-tumor immune response in small cell lung cancer2024
5Abstract 4776: Lurbinectedin alters EWS::FLI1 binding to chromatin to poison transcriptionOriginal Research · 2026